KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Current Deferred Revenue (2017 - 2023)

BeOne Medicines (ONC) has disclosed Current Deferred Revenue for 8 consecutive years, with $159.0 million as the latest value for Q2 2023.

  • On a quarterly basis, Current Deferred Revenue fell 2.67% to $159.0 million in Q2 2023 year-over-year; TTM through Jun 2023 was $159.0 million, a 2.67% decrease, with the full-year FY2022 number at $213.9 million, down 28.71% from a year prior.
  • Current Deferred Revenue was $159.0 million for Q2 2023 at BeOne Medicines, down from $185.5 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $300.0 million in Q4 2021 to a low of $17.5 million in Q1 2019.
  • A 4-year average of $141.4 million and a median of $159.0 million in 2023 define the central range for Current Deferred Revenue.
  • Biggest YoY gain for Current Deferred Revenue was 156.89% in 2022; the steepest drop was 28.71% in 2022.
  • BeOne Medicines' Current Deferred Revenue stood at $17.5 million in 2019, then soared by 1613.89% to $300.0 million in 2021, then dropped by 28.71% to $213.9 million in 2022, then decreased by 25.64% to $159.0 million in 2023.
  • Per Business Quant, the three most recent readings for ONC's Current Deferred Revenue are $159.0 million (Q2 2023), $185.5 million (Q1 2023), and $213.9 million (Q4 2022).